Product Description
The CleanPlex® Hypertrophic Cardiomyopathy (HCM) Panel is a pre-designed and made-to-order multiplex PCR / amplicon-based targeted sequencing (NGS) assay designed to examine the germline variants or mutations across 72 genes associated with Hypertrophic Cardiomyopathy (HCM). The panel targets all the exonic regions of those genes and the flanking intronic sequences. Compatible with just 10 ng of DNA, sequencing-ready libraries can be prepared using a streamlined workflow in just 3 hours. The pre-designed panel is optimized in silico to deliver data with high on-target performance and high coverage uniformity to ensure efficient use of sequencing reads.
This product is made to order. Once we receive your order, we will synthesize the panel and the kit will contain CleanPlex Multiplex PCR Primers and CleanPlex Targeted Library Kit. CleanPlex Indexed PCR Primers and CleanMag® Magnetic Beads can be ordered separately to complete the workflow from input DNA to sequencing-ready NGS libraries.
产品描述
CleanPlex®肥厚型心肌病（HCM）面板是一种预先设计和定制的多重PCR /基于扩增子的靶向测序（NGS）分析方法，旨在检查与肥厚型心肌病（HCM）相关的72个基因的种系变异或突变。该小组针对这些基因的所有外显子区域和侧翼内含子序列。仅需10 ng DNA即可兼容测序就绪的文库，只需3个小时即可使用简化的工作流程进行准备。预先设计的面板经过计算机优化，可提供具有高目标性能和高覆盖均匀性的数据，以确保有效利用测序读数。
该产品是定做的。收到您的订单后，我们将合成面板，该套件将包含CleanPlex Multiplex PCR引物和CleanPlex Targeted Library Kit。可以分别订购CleanPlex索引PCR引物和CleanMag®磁珠，以完成从输入DNA到可测序的NGS文库的工作流程。
Storage Temperature
Store at -20 °C.
For Research Use Only. Not for use in diagnostic procedures.
Gene List:
ACTC1, ACTN2, CAV3, CSRP3, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, PLN, PRKAG2, TCAP, TNNC1, TNNI3, TNNT2, TPM1, TTR, VCL, BAG3, DES, FHL1, FLNC, GAA, LDB3, ANKRD1, JPH2, MYH6, MYLK2, MYPN, NEXN, TTN, ABCC9, AGL, CACNA1C, CRYAB, KRAS, MYOZ2, PDLIM3, PTPN11, RAF1, RYR2, SOS1, BRAF, CALR3, DMD, DSC2, DSG2, DSP, DTNA, EMD, FKTN, GATA4, GATAD1, HRAS, ILK, JUP, LAMA4, LMNA, MAP2K1, MAP2K2, NEBL, NRAS, PKP2, RBM20, RIT1, SCN5A, SGCD, SHOC2, TAZ, TMEM43, TMPO
References:
Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-89.
Semsarian C. Update on the Diagnosis and Management of Hypertrophic Cardiomyopathy. Heart Lung Circ. 2018;27(3):276-279.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761-96.
Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and *****s. N Engl J Med. 2008;358(18):1899-908.
Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54.
Crocini C, et al. Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res Cardiol. 2013 May;108(3):349.
- 温馨提示：为规避购买风险，建议您在购买前务必确认供应商资质与产品质量。
- 免责申明：以上内容为注册会员自行发布，若信息的真实性、合法性存在争议，平台将会监督协助处理，欢迎举报